TRAUMEEL® PRODUCT MONOGRAPH52

Study design 138 physicians completed surveys for patients in their care receiving Traumeel®

tablets or drops 1,359 patients: 45.3% male, 54.6% female; age <21 12.8%, 21 40 35.2%,

41 60 32.5%, 61 80 16.6% and >80 2.8%. The most frequent complaint was bruises, followed in descending order of

frequency by sprains, degenerative joint disease, hematomas, carpal tunnel syndrome, frozen shoulder, post-traumatic edema, epicondylitis, and post-operative edema. Joint effusion, dislocations, concussion and bursitis were also treated.

Duration of symptoms was <1 week for approximately 50% of patients, between 1 week and 1 month for approximately 25%, and over 1 month for about 10%.

Traumeel® was supplemented with drug or non-drug therapies in approximately two thirds of patients; most frequently with analgesics, anti-inflammatories and medications for circulatory disorders as concomitant drug therapy and application of ice, electrotherapy and physical therapy as concomitant non-drug therapies.

Mode of application: tablets 69%, drops 29%, both forms 2%. Frequency of application: drops 94% between 5 drops 5 times daily and 30

drops 6 times daily; tablets 74% 1 tablet 3 times daily. Duration of treatment: ≤1 week 23%, 1 2 weeks 27%, 2 3 weeks 22%, 4 5

weeks 14%, 6 8 weeks 6%, >8 weeks 8%.

Outcome measures Time when symptoms began to improve. Physician-rated therapy outcome: very good, good, satisfactory,

unsuccessful, worsened.

Drug surveillance for Traumeel® oral treatment

Zenner S, Metelmann H. Oral treatment of traumatic, inflammatory, and degenerative conditions with a homeopathic remedy. Biol Ther. 1997;XV(1):22 26.

STUDY DESIGN FORMULATION INDICATION(S) Multi-center, prospective study.

Traumeel® tablets and drops.

Musculoskeletal injuries, inflammatory and degenerative joint conditions.